These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35475907)

  • 21. Efficacy of Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes Using Oral Carbohydrates During Automated Insulin Delivery With and Without Glucagon.
    Taleb N; Cheng R; Wu Z; Messier V; Desjardins K; Rabasa-Lhoret R
    Can J Diabetes; 2023 Jul; 47(5):445-450. PubMed ID: 37088417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Parchwani D; Dutta S; Singh R
    Expert Rev Clin Pharmacol; 2023 Jan; 16(1):61-71. PubMed ID: 36266088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study.
    Matsuhisa M; Takita Y; Nasu R; Nagai Y; Ohwaki K; Nagashima H
    Diabetes Obes Metab; 2020 Jul; 22(7):1167-1175. PubMed ID: 32115879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
    Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
    J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Nielsen CK; Øhrstrøm CC; Houji IJK; Helsted MM; Krogh LSL; Johansen NJ; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Care; 2023 Dec; 46(12):2208-2217. PubMed ID: 37819999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.
    Christiansen MP; Cummins M; Prestrelski S; Close NC; Nguyen A; Junaidi K
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
    Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
    Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
    Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
    J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
    [No Abstract]   [Full Text] [Related]  

  • 31. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
    Heller S; Battelino T; Bailey TS; Pieber TR; Hövelmann U; Plum-Mörschel L; Melgaard AE; Aronson R; DiMeglio LA; Johansen T; Danne T
    Diabetes Obes Metab; 2023 May; 25(5):1351-1360. PubMed ID: 36692230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
    Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
    Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of insulin basal rate reduction to reduce hypoglycemia during late post-prandial exercise in adults with type 1 diabetes using insulin pump therapy: A randomized crossover trial.
    Roy-Fleming A; Taleb N; Messier V; Suppère C; Cameli C; Elbekri S; Smaoui MR; Ladouceur M; Legault L; Rabasa-Lhoret R
    Diabetes Metab; 2019 Jun; 45(3):294-300. PubMed ID: 30165156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
    La Sala L; Pontiroli AE
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial.
    Fanelli CG; Pampanelli S; Porcellati F; Rossetti P; Brunetti P; Bolli GB
    Ann Intern Med; 2002 Apr; 136(7):504-14. PubMed ID: 11926785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?
    Gingras V; Desjardins K; Smaoui MR; Savard V; Messier V; Haidar A; Legault L; Rabasa-Lhoret R
    Acta Diabetol; 2018 Mar; 55(3):227-231. PubMed ID: 29224132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of Insulin-Induced Hypoglycemia in Type 1 Diabetes with Predictive Low Glucose Management System.
    Abraham MB; de Bock M; Paramalingam N; O'Grady MJ; Ly TT; George C; Roy A; Spital G; Karula S; Heels K; Gebert R; Fairchild JM; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
    Diabetes Technol Ther; 2016 Jul; 18(7):436-43. PubMed ID: 27148807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.